Skip to main content
. 2022 Oct 31;41(1):108–119. doi: 10.1002/hon.3089

FIGURE 1.

FIGURE 1

Study design. Cemi, cemiplimab; cHL, classic Hodgkin lymphoma (HL); DLBCL, diffuse large B‐cell lymphoma; DLT, dose‐limiting toxicity; Isa, isatuximab; PD‐1, programmed death‐1; PD‐L1, programmed death ligand‐1; PTCL, peripheral T‐cell lymphoma